Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Conducting Oncology Clinical Trials in Africa II: Twitter Workshop

Runcie C.W. Chidebe - Executive Director, Project PINK BLUE

Conducting Oncology Clinical Trials in Africa II: Twitter Workshop ( Runcie C.W. Chidebe - Executive Director, Project PINK BLUE )

Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin...

Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada

$Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma ( Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada )$

FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO...

Prof Robert Huddart and Dr Ignacio Durán

FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020 ( Prof Robert Huddart and Dr Ignacio Durán )

Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for...

Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA

Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma ( Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA )

High-dose twice daily thoracic radiotherapy in limited disease small-cell lung...

Prof Bjørn Henning Grønberg - Trondheim University Hospital, Trondheim, Norway

High-dose twice daily thoracic radiotherapy in limited disease small-cell lung cancer ( Prof Bjørn Henning Grønberg - Trondheim University Hospital, Trondheim, Norway )

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

Background of the KEYLYNK-007 trial for advanced solid tumours

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

Background of the KEYLYNK-007 trial for advanced solid tumours ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in...

Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib ( Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA )

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1...

Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis ( Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany )

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )

OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase...

Prof Jorge Cortes - Augusta University, Augusta, USA

OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid leukaemia ( Prof Jorge Cortes - Augusta University, Augusta, USA )

VIALE-A: Venetoclax with or without in treatment-naïve patients with acute...

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myeloid leukaemia ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )

More from ecancer